SCHEMBL3474886

SCHEMBL3474886

O=c1cc(-c2ccccc2)[nH]c(=O)[nH]1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS2R38 P59533 1/20 0.66
KDM4E B2RXH2 4/20 0.57
GAA P10253 2/20 0.57
MAPT P10636 1/20 0.57
TDP1 Q9NUW8 1/20 0.57
HPGD P15428 4/20 0.53
HSD17B10 Q99714 3/20 0.53
ALDH1A1 P00352 2/20 0.53
PLA2G10 O15496 1/20 0.52
NOTUM Q6P988 1/20 0.52
CTSV O60911 1/20 0.48
LMNA P02545 1/20 0.48
TUBB4A P04350 1/20 0.48
TP53 P04637 1/20 0.48
TUBB P07437 1/20 0.48
CTSL P07711 1/20 0.48
TUBA3C P0DPH7 1/20 0.48
TUBA1B P68363 1/20 0.48
TUBA4A P68366 1/20 0.48
TUBB4B P68371 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13917978 0.81 GPR84 (0.52) TAS2R38KDM4EGAAMAPTTDP1
SCHEMBL10718041 0.79 ERCC1 (0.49) TAS2R38KDM4EGAAMAPTTDP1
SCHEMBL1006272 0.79 TAS2R38 (1.00) TAS2R38KDM4EGAAMAPTTDP1
SCHEMBL4482962 0.79 MAPT (0.51) TAS2R38KDM4EMAPTHPGDHSD17B10
SCHEMBL6756097 0.78 TAS2R38 (0.60) TAS2R38KDM4EGAAMAPTTDP1
SCHEMBL29948606 0.76 TAS2R38 (0.58) TAS2R38KDM4EGAAMAPTTDP1
SCHEMBL5907056 0.75 TAS2R38 (0.56) TAS2R38KDM4EGAAMAPTTDP1
SCHEMBL23772153 0.75 GPR84 (0.49) TAS2R38KDM4EALDH1A1NOTUMLMNA
SCHEMBL25619763 0.75 HDAC6 (0.43) TAS2R38KDM4EGAAMAPTHPGD
SCHEMBL9371336 0.75 TAS2R38 (0.55) TAS2R38KDM4EGAAMAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0343050-B1 6-PHENYL-3-PIPERAZINYLALKYL 1H,3H-PYRIMIDINEDIONE-2,4 DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THERAPY SYNTHELABO (FR) 1992-12-02 EP claimed
EP-4182737-B1 OPTICALLY ACTIVE DEVICES AMO Ireland (IE) 2024-07-03 EP disclosed
US-20230273456-A1 OPTICALLY ACTIVE DEVICES JOHNSON & JOHNSON SURGICAL VISION INC (US) 2023-08-31 US disclosed
US-20230273456-A1 OPTICALLY ACTIVE DEVICES JOHNSON & JOHNSON SURGICAL VISION INC (US) 2023-08-31 US disclosed
US-20230273455-A1 OPTICALLY ACTIVE DEVICES JOHNSON & JOHNSON SURGICAL VISION INC (US) 2023-08-31 US disclosed
US-20230273455-A1 OPTICALLY ACTIVE DEVICES JOHNSON & JOHNSON SURGICAL VISION INC (US) 2023-08-31 US disclosed
US-8334292-B1 Pyrimidine compounds and methods of making and using same CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) 2012-12-18 US disclosed
US-8334292-B1 Pyrimidine compounds and methods of making and using same CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) 2012-12-18 US disclosed
US-20100324076-A1 Novel sEH Inhibitors and their Use GLAXOSMITHKLINE LLC 2010-12-23 US disclosed
EP-2240021-A1 NOVEL SEH INHIBITORS AND THEIR USE GlaxoSmithKline LLC (US) 2010-10-20 EP disclosed
US-4950670-A Psychological and cardiovascular disorders SYNTHELABO (FR) 1990-08-21 US disclosed
EP-0172427-B1 PROCESS FOR PRODUCTION OF VINYL CHLORIDE POLYMER Shin-Etsu Chemical Co., Ltd. (JP) 1989-07-05 EP disclosed
US-4758639-A Process for production of vinyl polymer SHIN-ETSU CHEMICAL CO., LTD. (JP) 1988-07-19 US disclosed
US-4757124-A Suspension or emulsion polymerizing vinyl chloride monomer or mixture of vinyl chloride with vinyl monomer copolymerizable therewith in reactor with walls coated with antiscaling compound containing dye or pigments SHIN-ETSU CHEMICAL CO., LTD. (JP) 1988-07-12 US disclosed
US-4625028-A 6-aryluracils and selected novel intermediates used in the preparation thereof THE UPJOHN COMPANY (US) 1986-11-25 US disclosed
US-4593030-A Use of 6-aryluracils as antiinflammatory and antiarthritic agents THE UPJOHN COMPANY (US) 1986-06-03 US disclosed
US-4578466-A Processes for the preparation of 6-aryluracils THE UPJOHN COMPANY (US) 1986-03-25 US disclosed
EP-0172427-A2 Process for production of vinyl chloride polymer Shin-Etsu Chemical Co., Ltd. (JP) 1986-02-26 EP disclosed
US-4521599-A Process for the preparation of 1,3-oxazine-4-ones THE UPJOHN COMPANY (US) 1985-06-04 US disclosed
US-4495349-A 6-Aryluracils THE UPJOHN COMPANY (US) 1985-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230273456-A1 OPTICALLY ACTIVE DEVICES PDE6C, PDE6D, PDE6A TAS2R38 4055/4885KDM4E 3198/4885GAA 1954/4885
US-20100324076-A1 Novel sEH Inhibitors and their Use EPHX1, NCEH1, PCSK9 TAS2R38 4790/4885KDM4E 886/4885GAA 480/4885
US-20230273455-A1 OPTICALLY ACTIVE DEVICES PDE6C, PDE6A, PDE6D TAS2R38 3988/4885KDM4E 3587/4885GAA 1811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.